US retinal diseases focussed start-up Opus Genetics has acquired the rights to two pre-clinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. 29 December 2022
Shares of Jounce Therapeutics were trading up a massive 72% at $1.27 pre-market, on the news that biotech major Gilead Sciences is amending an existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020. 28 December 2022
Germany’s Merck KGaA has embarked on a new research collaboration with Mersana Therapeutics (Nasdaq: MRSN), including terms for a commercial license. 23 December 2022
Respiratory disease specialist Verona Pharma has seen its shares jump from around $13 to $18 following positive results from the Phase III ENHANCE-1 trial. 21 December 2022
US clinical-stage biotech Magenta Therapeutics has halted dosing in one of the groups taking part in a Phase I/II study of cancer candidate MGTA-117. 21 December 2022
US biotech major Gilead Science today revealed that its Kite subsidiary has reached agreement to acquire privately-held Tmunity Therapeutics, a start-up set up by Carl June and his colleagues at the University of Pennsylvania and with former Novartis heavyweight Usman ‘Oz’ Azam as chief executive. 20 December 2022
Californian companies Gilead Sciences and Arcus Biosciences have announced positive results from the fourth interim analysis of the ARC-7 study. 20 December 2022
Ireland-based cancer focused biopharma Carrick Therapeutics and family-owned Italian pharma Menarini have announced a clinical trial collaboration and supply agreement. 20 December 2022
Switzerland-based Idorsia today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, the firm’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension. 20 December 2022
Shares of Pennsylvania, USA-based liver disease specialist Madrigal Pharmaceuticals skyrocketed 270% to $227.90 after reporting success in non-alcoholic steatohepatitis (NASH), a therapy sector that so far has been littered with disappointments. 19 December 2022
Clinical-stage US biotech Mustang Biotech, which is focused on cell and gene therapies for hematologic cancers, solid tumors and rare genetic diseases, today provided updates on its CAR-T portfolio and 2023 anticipated milestones. 19 December 2022
The European Commission (EC) has granted marketing authorization for Ebvallo (tabelecleucel)vas a monotherapy for treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein Barr virus positive post transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. 19 December 2022
Shares of Innate Pharma were almost 14% higher at 2.34 euros by late morning on the news that it has expanded its collaboration with fellow France-based pharma major Sanofi. 19 December 2022
Cratering shares in Cambridge, Massachusetts-based inflammatory disease company Third Harmonic Bio reflect a loss in confidence after a Phase I failure. 16 December 2022
Pennsylvania, USA-based CNS specialist Vallon Pharmaceuticals’ stock price soared an initial 230% to $0.85, after the company unveiled plans to merge its operations with privately-held biotech GRI Bio in an all-stock transaction. 15 December 2022
A Danish company developing a vaccine against group B streptococcus (GBS) - an infection often known as Strep B - has 72 million ($77 million) euros more to spend. 15 December 2022
French drug resistance specialist Ribonexus has appointed Steven Powell as chief executive, as the company prepares to seek more financing for its small molecule programs. 14 December 2022
US clinical stage biotech Praxis Precision Medicines’ shares closed up nearly 5% yesterday and rose a further 2.3% to $2.25 pre-market, on the news of a strategic collaboration with Belgium’s UCB, based on Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. 14 December 2022
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024